• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ingevity Corporation (Amendment)

    1/22/24 2:03:06 PM ET
    $NGVT
    Major Chemicals
    Industrials
    Get the next $NGVT alert in real time by email
    SC 13G/A 1 us45688c1071_012224.txt us45688c1071_012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) INGEVITY CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 45688C107 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45688C107 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 5934518 (6) Shared voting power 0 (7) Sole dispositive power 6003674 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 6003674 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 16.6% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- INGEVITY CORPORATION Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 4920 O'HEAR AVENUE, SUITE 400 NORTH CHARLESTON SC 29405 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 6003674 Percent of class 16.6% Number of shares as to which such person has: Sole power to vote or to direct the vote 5934518 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 6003674 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The interest of 1 such person, iShares Core S&P Small-Cap ETF, in the common stock of INGEVITY CORPORATION is more than five percent of the total outstanding common stock. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 22, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Life Limited Aperio Group, LLC BlackRock Advisors, LLC BlackRock (Netherlands) B.V. BlackRock Fund Advisors* BlackRock Institutional Trust Company, National Association BlackRock Asset Management Ireland Limited BlackRock Financial Management, Inc. BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Investment Management (Australia) Limited BlackRock Fund Managers Ltd *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $NGVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NGVT

    DatePrice TargetRatingAnalyst
    2/26/2025$62.00 → $65.00Market Perform → Outperform
    BMO Capital Markets
    8/7/2024$58.00Market Perform → Market Outperform
    CJS Securities
    4/22/2024$52.00 → $62.00Hold → Buy
    Jefferies
    11/6/2023$49.00Market Outperform → Market Perform
    CJS Securities
    10/3/2023$62.00 → $53.00Buy → Hold
    Loop Capital
    8/7/2023$71.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/27/2023$64.00 → $75.00Hold → Buy
    Loop Capital
    5/5/2023$92.00 → $64.00Buy → Hold
    Loop Capital
    More analyst ratings

    $NGVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces appointment of David H. Li as president and CEO

      Li brings 25-year+ record of driving successful corporate transformation, long-term growth and stockholder value creation at premier global specialty materials supplier Ingevity Corporation (NYSE:NGVT) today announced that its board of directors has appointed David H. Li as the company's president and CEO, effective as of April 7, 2025, and that he is expected to join the board of directors following the 2025 Annual Meeting. Li succeeds Ingevity board member, Luis Fernandez-Moreno, who has been serving as interim president and CEO since October 2024. Fernandez-Moreno will remain on Ingevity's board. This press release features multimedia. View the full release here: https://www.businesswir

      3/10/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Highlights Significant Momentum on Actions Underway to Drive Improved Performance and Value Creation

      Delivered Record Year in Performance Materials and Strategic Repositioning in Performance Chemicals Is Already Demonstrating Results Business Portfolio Review Is Progressing with Recently Announced Strategic Alternatives Process for Industrial Specialties Product Line and Evaluation of Additional Portfolio and Cost Reduction Actions Ongoing Provides Information About Engagement with Vision One Ingevity Corporation (NYSE:NGVT) today issued the following letter to stockholders in response to the presentation issued by Vision One Management Partners ("Vision One") earlier today: Dear Ingevity Stockholders, The Ingevity Board of Directors and leadership team are committed to taking ag

      2/25/25 4:21:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Financials

    Live finance-specific insights

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity reports fourth quarter and full year 2024 financial results

      Fourth Quarter: Net sales of $298.8 million decreased 20% compared to prior year primarily due to repositioning actions in the Performance Chemicals segment that resulted in the exit of lower-margin end markets Net income of $16.6 million and diluted earnings per share (EPS) of $0.46, including pre-tax restructuring charges of $23.4 million; adjusted earnings of $34.7 million and diluted adjusted EPS of $0.95 Adjusted EBITDA of $80.6 million and adjusted EBITDA margin of 27.0% Operating cash flow of $64.5 million and free cash flow of $39.6 million, which included the second and final $50.0 million installment of a termination fee for a long-term crude tall oil (CTO) supply agreemen

      2/18/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    SEC Filings

    See more
    • SEC Form S-8 filed by Ingevity Corporation

      S-8 - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:16:03 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Ingevity Corporation

      S-8 POS - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:15:57 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Ingevity Corporation

      10-Q - Ingevity Corp (0001653477) (Filer)

      5/6/25 4:24:35 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blackwell Jean was granted 4,057 shares, increasing direct ownership by 145% to 6,857 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:42:08 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Fernandez-Moreno Luis M was granted 4,057 shares, increasing direct ownership by 8% to 53,105 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:38:06 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Lynch Frederick J was granted 4,057 shares, increasing direct ownership by 18% to 26,359 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:33:42 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/12/24 3:54:24 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/4/24 11:52:25 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Ingevity Corporation (Amendment)

      SC 13D/A - Ingevity Corp (0001653477) (Subject)

      2/28/24 5:30:32 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ingevity upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Ingevity from Market Perform to Outperform and set a new price target of $65.00 from $62.00 previously

      2/26/25 7:15:06 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by CJS Securities with a new price target

      CJS Securities upgraded Ingevity from Market Perform to Market Outperform and set a new price target of $58.00

      8/7/24 9:18:13 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by Jefferies with a new price target

      Jefferies upgraded Ingevity from Hold to Buy and set a new price target of $62.00 from $52.00 previously

      4/22/24 7:39:26 AM ET
      $NGVT
      Major Chemicals
      Industrials